MLC901 for Moderate to Severe Traumatic Brain Injury (Specified Drug Code)
Status:
Recruiting
Trial end date:
2020-10-01
Target enrollment:
Participant gender:
Summary
Patients with a diagnosis of moderate to severe traumatic brain injury (TBI) will be
enrolled. Subjects will be randomly assigned to receive either MLC901 (Specified Drug Code)
or placebo capsules three times per day over 6 months. Evaluation of patients will be carried
out at baseline as well as at 3-month and 6-month follow-up visits. Modified Rankin Scale
(mRS) and Glasgow outcome scale (GOS) will be used to examine patients. Efficacy will be
evaluated by comparing these two scores between the 2 groups at follow-up visits.